

## **10 February 2014**

**CMP:** Rs.57

**Industry:** Healthcare services

**BSE** group: B


#### **Promoters**

Ashok Kumar Goenka, Banwarilal Goenka and Rajesh Goenka

Key Data (as on 11 Nov' 13)

itty Data (as on 11 ivov 1.	<i>-</i> /
BSE	530897
ISIN	INE825C01018
Face Value (Rs.)	10.0
Mkt Cap (Rs. mn)	191.0
Current P/E	9.7
Current P/BV	1.4
52 week low-high	42.00-79.75
30 days avg daily trading volume	2558
Equity capital (Rs mn)	33.5
Net worth (Rs mn)	141.8

# **Shareholding Pattern (%)**



Click here for: Initiation Report

Write to us at: equity.research@outlook.com

## **Company business**

N G Industries Ltd (NGIL) is a healthcare service company based in Kolkata. NGIL operates nursing homes, infertility clinics and retail pharmacy outlets in India. Its first business division – 'N G Medicare and Calcutta Hope Infertility Clinic', started in 1995, is a complete diagnostic centre with day-care and nursing home facilities. In 2006, through 'N G Nursing Home', it increased its presence in the healthcare services space. NG Nursing Home caters to major surgeries including general surgery, joint replacement, and urology. Its third business unit – 'N G Pharmacy' has two retail outlets across Kolkata.

## **Financials**

Particulars (Rs in mn)	Jul '13 to Sep '13	Jul '12 to Sep '12	% Change <sup>1</sup>	Apr'13 to Jun '13	% Change <sup>2</sup>
Total income	38.7	42.8	(9.6%)	35.2	9.9%
Total operating expenditure	27.9	30.8	(9.4%)	26.8	4.1%
EBIDTA	10.8	12.0	(10.0%)	8.4	28.6%
EBIDTA margin	27.91%	28.04%	(0.5%)	23.86%	17.0%
PBT	7.6	10.2	(25.5%)	5.3	43.4%
PAT	6.1	7.5	(18.7%)	4.0	52.5%
PAT margin	15.76%	17.52%	(10.0%)	11.36%	38.7%
Cash accruals	8.5	9.2	(7.6%)	6.2	37.1%
EPS	1.8	2.2	(18.8%)	1.2	52.1%


<sup>&</sup>lt;sup>1</sup> compared to corresponding quarter in the previous year

Source: Moneycontrol, Company

#### **Financial Performance**

On y-o-y basis, the total income of the company decreased by 9.6% to Rs 38.7 mn for the quarter ended September 2013 from Rs 42.8 mn for the corresponding quarter previous year. EBIDTA decreased by 10% to Rs 10.8 mn for Sep13 quarter form Rs 12.0 mn for Sep12 quarter on yearly basis. However, EBIDTA margin has remained unchanged at around 28%. Net profit for the quarter ended September 2013 was Rs 6.1 mn, down 18.7% from Rs 7.5 mn for the same quarter previous year. EPS increased by 18.8% to Rs 1.8 from Rs 2.2.

#### **Share Price Performance**



<sup>&</sup>lt;sup>2</sup> sequential comparisons





## **Financials**

P&L (Rs. mn)	FY11	FY12	FY13
Total income	118.5	144.9	149.0
EBIDTA	32.8	40.8	36.8
EBIDTA margin	28%	28%	25%
Depreciation	7.5	7.3	7.3
EBIT	25.3	33.5	29.5
Interest	0.2	0.3	1.2
PBT	25.1	33.2	28.3
Tax	6.5	7.0	7.5
PAT	18.6	26.2	20.8
PAT Margin	16%	18%	14%
	-	-	-
Dividend Payout	73.1	51.9	65.4

Valuation ratios	FY11	FY12	FY13
P/E	7.8	11.6	9.6
P/BV	1.7	1.8	1.3

Balance Sheet (Rs. mn)	FY11	FY12	FY13
Share Capital	33.5	33.5	33.5
Share application money, warrants	0.0	0.0	0.0
Reserves & Surplus	88.6	101.1	108.3
Net worth	122.1	134.6	141.8
Borrowings	5.7	15.7	47.6
Current Liabilities and provisions	15.1	16.0	15.4
Net deferred tax Liabilities	0.0	0.0	0.0
Total liabilities	142.9	166.3	204.8
Fixed assets	42.7	43.7	64.4
Non-current Investments	78.6	79.8	96.7
Loans and Advances	12.0	13.2	11.9
Current Assets	8.6	28.3	30.5
Total assets	142.9	166.3	204.8
Cash Flow (Rs.mn)	FY11	FY12	FY13
PBT	25.1	33.2	28.3
CF from Operation	18.6	19.4	18.4
CF from Investment	(6.9)	2.6	(37.4)
CF from Financing	(12.1)	(1.8)	20.2
Inc/(dec) Cash	(0.4)	20.2	1.2

## Disclaimer

**Closing Balance** 

The information contained herein is from publicly available data or other sources believed to be reliable, but we do not represent that it is accurate or complete and it should not be relied on as such. Our company shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for any investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigation as it deems necessary to arrive at an independent evaluation which may affect their investment in the securities of companies referred to in this document (including the merits and risks involved). The discussions or views expressed may not be suitable for all investors. This information is strictly confidential and is being furnished to you solely for your information.

21.8

1.6

23.0